Pay in 4 interest-free payments of $6.12 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
As the field evolves, its crucial for healthcare leaders and organizations to stay agile, adapt to new trends, and focus on what matters most for patients and providers, namely: GLP1s are now firstline therapies: Adoption has accelerated from just 3% in 2021 to more than 23% in 2025, displacing longstanding generics like metformin
Peptides 2023;162:170955.ArticlePubMed 109
GLP-1 usually only increases insulin production when blood glucose levels are high [11]
Moreover, the combined treatment of sDPP4 and LPS leads to increased expression and secretion of the pro-inflammatory cytokines, TNF and IL-6
Epidemiological evidence from large cohort studies The strongest population-level evidence comes from a study published on medRxiv that compared allodynia incidence between GLP-1 receptor agonist users and users of bupropion-naltrexone, an alternative weight management medication
A rare hormonal disorder, acromegaly is often caused by a tumor in the pituitary gland
US$ 28.25
US$ 21.56
US$ 28.56
US$ 26.05
US$ 29.10
